Overview

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Status:
Not yet recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1a/b, multicenter, open-label, first-in-human, dose escalation, expansion and extension study to evaluate the safety, tolerability, and DLTs to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and preliminary efficacy of IBI343 (study drug) in participants with locally advanced unresectable or metastatic solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.